A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Acronyms AZD3293 hADME
- Sponsors AstraZeneca
- 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 May 2014 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 05 May 2014 New trial record